Antibiotics that interfere reversibly with various aspects of ribosomal function (chloramphenicol, tetracycline, erythromycin, and spectinomycin) are shown to antagonize, at barely inhibitory concentrations, the inhibitory effect of low concentrations of streptomycin (SM) on the growth of Escherichia coli. Paradoxically, these compounds can also replace SM in supporting the growth of conditionally SM-dependent mutants. Chloramphenicol produced about as much phenotypic suppression as SM in SM-sensitive strains, but less than that attainable with high concentrations of SM in resistant strains. The antagonism to SM inhibition and the phenotypic suppression appear to be specific for those growth inhibitors that act on the ribosome. Since inhibitors of the 50S subunit of the ribosome (chloramphenicol, erythromycin) are as active as inhibitors of the 30S subunit, it is suggested that phenotypic suppression by borderline concentrations of ribosome inhibitors does not necessarily depend on an alteration of the recognition region of the ribosome. Alternatively, partial inhibition of the ribosomes might change the environment in a way that would influence the frequency of misreading. Phenotypic suppression by a low concentration of SM as well as by chloramphenicol was found to depend on the presence of a trace of the required growth factor.
The well-known ability of reversible inhibitors of the ribosome, such as chloramphenicol (CA), to antagonize the bactericidal action of streptomycin (SM; references 1, 18, 23) seemed to be explained by the suggestion that this killing results from the production of abnormal protein (8, 14) . This bactericidal mechanism, however, appears to be eliminated by the finding that the bactericidal and the misreading effects of the drug can be dissociated from each other in several ways (reviewed in 9); in particular, puromycin prevents protein formation and yet permits rapid killing (34, 35) . An alternative mechanism is suggested by the observation that actinomycin D, in contrast, prevents killing (unpublished observations). Since this drug causes the ribosomes to be inactive for lack of messenger ribonucleic acid (RNA), whereas puromycin permits ribosomal activity, the irreversible effect of SM appears to require active engagement of the ribosomes in their cycle of protein synthesis.
Accordingly, the antagonism of ribosomal I Present address: Rogoff Institute, Beilinson Hospital, Petach
Tikvah, Israel. inhibitors to the lethal action of SM evidently depends on their ability to block the ribosome cycle. Some additional explanation, however, seems to be required for two further effects, which will be described in the present paper. At borderline, partly inhibitory concentrations, these drugs can antagonize the inhibition of the growth of SM-sensitive Escherichia coli cells by low concentrations of SM; and they can also replace SM in causing phenotypic suppression of conditionally SM-dependent (CSD) mutants. Possible mechanisms will be discussed. (Fig. 3) . The response to an excess of SM (100 ,g) was faster as well as heavier, but as with most CSD mutants (14) , it was still slower than the response to the required amino acid.
Requirement for a trace of end product in the response to SM or to CA. In the experiment of Fig. 3 , the inoculum was 0.1 ml of an unwashed (3, 19) , it seemed possible that CA could be antagonizing SM only indirectly, as a result of depressing the growth rate. Accordingly, other bacteriostatic drugs were similarly tested against borderline concentrations of SM. Similar, though weaker, antagonism was produced by three additional drugs that inhibit protein synthesis reversibly on the ribosome: tetracycline, erythromycin, and spectinomycin (Table 1) . Sodium azide, which inhibits electron transport, also antagonized inhibition by SM. In contrast, no such effect could be seen with several other drugs: novobiocin, which reversibly inhibits DNA and RNA synthesis (25, 26) ; sulfadiazine, which inhibits (via folic acid) the biosynthesis of various nucleotides and amino acids; or puromycin or 5-methyltryptophan, which inhibit protein synthesis by mechanisms that do not involve inhibition of a ribosomal function. Antagonism to inhibition of growth by SM is thus apparently restricted to drugs that inhibit the ribosome or that shift metabolism to an anaerobic pattern. (2) + (1) + (3) + (2) + (3) + (3) + (1) + (1) a An overnight culture grown in minimal medium was plated at 105 cells/ml in the same medium solidified with 1.5% agar. The medium contained SM at the concentration noted. The various drugs were applied on filter paper discs on the surface, in an amount that gave a small zone of inhibition on an SM-free plate. The plates were incubated and growth was checked daily for 4 days. bNumbers in parentheses indicate days when growth was first observed.
culture of a CSD methionine auxotroph, grown in a medium containing an excess of methionine.
Much lighter inocula (10-to 101 ml), in contrast, failed to respond to CA. Since the smaller inocula contained less free methionine as well as fewer cells, washed cells were tested. Even with heavy inocula, such cells did not respond to CA unless the medium was supplemented with a trace (0.05 gg/ml) of the required amino acid ( Table   2 ). Measurements of growth response in liquid medium showed that this supplement would support only a doubling of the largest inoculum (107 cells/ml) used in Table 2 . It is evident that traces of growth factor in the inoculum have an important role in the test for phenotypic suppression.
A similar requirement for "primer" amino acid was observed (see Table 3 ) with a number of other mutants but not with three lysine auxotrophs that were incompletely blocked (i.e., that grew in liquid minimal medium with a doubling time of 7 hr and yielded visible growth on solid minimal medium within 4 to 5 days). This "leakiness" evidently provides the background growth required for weak phenotypic suppression.
With a small amount of SM, phenotypic suppression was found to depend similarly on a small supply of end product (Table 2) . However, 500 ,ug of SM elicited a response even in the absence of end product, though considerably more slowly than in its presence.
Response of various strr and str5 (SM-sensitive) auxotrophs to SM and to CA. Seventeen randomly chosen CSD amino acid auxotrophs, derived from an strr mutant of E. coli B (14) , were similarly tested. All but one of these strains responded to a small amount of CA or of SM (Table 3) . Moreover, distinct and reproducible differences were seen in the relative response of various mutants to the two drugs. Thus, CSD-leu-2 and CSDleu-5, which could be shown to be "leaky," responded to SM even without amino acid sup Table 2 , with the required amino acid present where indicated at 0.1 or 1.0,pg/ml. The plates were incubated and were checked daily for growth around the discs, which contained CA (4 jg) or SM (5 ,g). The results were qualitatively the same at 2 and at 4 days.
tectably to CA, even with such supplementation. In contrast, CSD-met-12 responded to CA but not to SM; CSD-met-2 responded to either but more heavily to CA. Finally, arginine auxotroph CSD-B4S-7 did not respond to either SM (15) or CA under these conditions, although it did respond to a high concentration of SM (14) .
At low concentrations, SM can also cause phenotypic suppression in certain auxotrophs of strs strains (16) . Six such mutants were tested with CA, and all responded ( Table 3 ). The responses were equally strong with either drug, in the low concentrations that could be tolerated. A detectable response required primer amino acid with all but strain argCSD-B40-1. In the absence of primer, this exception responded more strongly to CA than to SM.
It has been reported (14, 16) that only a small fraction (< 1 %) of all auxotrophs exhibit phenotypic suppression by SM. The response to CA seems to be restricted to the same set of mutants. Thus, when 10 randomly chosen amino acid auxotrophs of str8 E. coli W were tested, none responded to CA (or to SM).
Effect of other compounds. Tetracycline, erythromycin, and spectinomycin, which (like CA) can antagonize the inhibition of the growth of sensitive strains by borderline concentrations of SM (Table 1) , were also found to stimulate the growth of over half of the CSD mutants tested (Table 4) . The responses, however, were generally weaker than to CA. Some strain specificity could be seen, just as in the earlier comparison of CA and a small amount of SM (Table 3) ; CSD-his-3 responded to tetracycline and to erythromycin but not to spectinomycin, whereas the opposite was true of CSD-his-1 (Table 4 ). Puromycin, which had not antagonized SM inhibition (Table 1) , very weakly stimulated growth of some strains; this drug acts on the ribosome, but not by blocking its cycle.
Several derivatives of CA were also tested, at 100 ,g per disc, with those mutants that had proved most responsive to CA: CSD-lys-1, CSDlys-2, CSD-lys-3, and CSD-met-1. With all four mutants, growth was stimulated by the derivatives that inhibited growth of the wild type (CA with a monochloroacetyl or a trifluoroacetyl group substituted for the dichloroacetyl group), but not by the compounds that did not inhibit wild-type growth (CA without the dichloroacetamido group, CA with the nitro replaced by an amino group, and the L-erythro isomer of CA).
To determine whether the response is secondary to slowing of growth from any cause or is specific for ribosome inhibitors, several other kinds of growth inhibitors were tested, as in Table 3 , in amounts that would give a small zone of inhibition in complete medium. Sodium azide (50 ,ug/disc) and 5-methyltrytophan (0.25 ,ug/disc) did not stimulate growth of any strains. Novobiocin (100 ,ug/disc) stimulated only the leaky CSD mutants (lys-1, lys-2, and lys-3), and more feebly than any of the ribosomal reagents.
Growth stimulation in liquid medium: enzyme assays. When studied in liquid medium, several completely blocked strr-CSD strains exhibited no response to low concentrations of CA (1 ,g/ml) or of SM (5 to 30 ,ug/ml). Stimulation was observed, however, with an incompletely blocked mutant, CSD-lys-2. In minimal medium supplemented with SM (30 ,g/ml), this strain grew at the normal rate (doubling time 54 min; Fig. 4) , just as when supplemented with the required end product; without supplementation, it grew at first one-third as fast and, after several hours, more slowly. It is seen that CA at 1 ,ug/ml also stimulated growth, but much more weakly and after a considerable lag.
Since SM at a high concentration can demonstrably restore synthesis of an active form of a mutant enzyme in CSD mutants (13, 14) , similar restoration was sought in a mutant suppressed by CA in liquid medium. In the experiment of Fig. 4 , 
Plates were prepared as in Table 2 (107 cells/ml), with the required amino acid added, where indicated, at 0.1 or 1.0 ;sg/ml. Each drug was applied in an amount that gave a small zone of inhibition of growth in complete medium. The growth response was recorded after 2 days of incubation; after 2 days more, no qualitative change was seen. I All the mutants of Table 3 were tested, except that the six str strains were not tested (NT) with tetracycline or erythromycin. The mutants of (Fig. 4) , among several CSD mutants that responded in solid medium. Moreover, in the CA-stimulated cells, the activity of the mutant enzyme (diaminopimelate decarboxylase) was too low to be detected in extracts, whereas, with SM at 30 ,ug/ml, which stimulated faster growth, restoration of mutant enzyme activity was readily detected.
The antagonism to SM appears to be specific for inhibitors that act on the ribosome; no effect was obtained with borderline concentrations of several compounds that slow growth in other ways, including sulfonamides, 5-methyltryptophan (which blocks the synthesis of tryptophan; reference 22), novobiocin (25, 26) , and puromycin. The specificity of the phenotypic suppression was similar, except that puromycin and novobiocin very weakly stimulated the growth of some incompletely blocked CSD mutants.
It seems very unlikely that reversible inhibitors produce the effects described here by being bound to the same ribosomal site as SM; the effective compounds differ widely in structure from SM, and they also appear to act on different parts of the ribosome. Thus, although spectinomycin acts, like SM (6), on the 30S subunit (7), the mechanism is quite different (2) , and mutations to SM resistance and those to spectinomycin resistance alter different molecules in the 30S subunit (27) . Tetracycline also appears to act on the 30S subunit, for more of it is bound tightly by this subunit than by the 50S subunit (4, 11, 12, 20) , and it inhibits the binding of aminoacyl transfer RNA to 305 subunits (29) as well as to ribosomes (17, 28) . However, it clearly differs from SM in its mechanism of action (which is not bactericidal) and hence in its binding site. CA and erythromycin act at more remote sites, since they bind specifically to the 50S subunit (31, 33) ; moreover, CA appears to block directly the peptide-forming step (5, 32) , and erythromycin the translocation step (5) .
Although the various reversible inhibitors thus bind to different sites on the ribosome, the resulting changes in these sites might conceivably have a similar allosteric effect on the SM-binding site, resulting in both a decrease in affinity for SM and a stimulation of misreading. Such a direct mechanism, involving increased ribosomal ambiguity, is favored by the observation that various reversible inhibitors of the ribosome differ somewhat from each other (Table 4) , as well as from SM (Table 3) , in their relative activity in supporting growth of different CSD mutants. In similar auxanographic tests, a neomycin-dependent mutant of E. coli has been reported to respond to macrolides but not to CA or tetracycline (24) .
Nevertheless, it would seem remarkable if the SM-binding site (in the recognition region of the 30S subunit) could be distorted by inhibitors that bind to the 50S subunit (CA, erythromycin) just as by those that bind to the 30S subunit (tetracycline, spectinomycin). Hence, even though such distortion is almost certainly the cause of phenotypic suppression by those ribosomal reagents that do not inhibit the ribosomes (e.g., SM acting on strr cells), those that do inhibit might suppress by a more indirect mechanism; for if some ribosomes are blocked, or if all are slowed, the remaining ribosomal activity will occur in an altered environment. For example, CA causes an increase in the charging of transfer RNA in cells (21) , which could promote suppression by influencing the competition of various species of aminoacyl-transfer RNA with each other or with a polypeptide-releasing protein. Moreover, these considerations may apply not only to reversible ribosomal inhibitors, but also to SM acting at sublethal concentrations on str' CSD cells. However, such an indirect mechanism might not be able alone to account for the relatively high levels of restoration of mutant enzyme activity that have been observed in some strB strains (13) .
An indirect mechanism could also account for the antagonism of borderline concentrations of reversible ribosome inhibitors to the inhibition of growth by SM (Fig. 2) . For example, cells partly inhibited by CA develop an increased content of RNA (30) , which might raise the threshold of growth inhibition by SM, since this drug complexes readily with RNA.
In the course of this work we observed that the suppression of CSD amino acid auxotrophs by CA, or by SM at low concentrations, requires a small amount of "primer" amino acid (except with incompletely blocked mutants, which can provide their own primer). Since the supplement is effective in an amount ( Table 2) that can support only a doubling of the inoculated cells, it cannot be acting simply by adding its limited yield of growth to that supported by the drug. Evidently the frequency of "correction" of a mutant protein, which is less than 1% for a high con-centration of SM (14) , must be so low for CA that its effect on the low rate of translation supported by protein turnover fails to yield enough active enzyme to initiate growth. During the protein synthesis supported by the primer, however, the suppressor has an increased opportunity to cause the cell to make some active enzyme. Since the product of this enzyme should then be able to supplant the primer, growth understandably becomes self-perpetuating in the continuing presence of the suppressor. Hence, it seems desirable to include a trace of primer in tests for phenotypic suppression.
